|
1
|
DiMarco-Crook C and Xiao H: Diet-based
strategies for cancer chemoprevention: The role of combination
regimens using dietary bioactive components. Annu Rev Food Sci
Technol. 6:505–526. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mukhtar H and Ahmad N: Cancer
chemoprevention: Future holds in multiple agents. Toxicol Appl
Pharmacol. 158:207–210. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Adhami VM, Ahmad N and Mukhtar H:
Molecular targets for green tea in prostate cancer prevention. J
Nutr. 133(Suppl): 2417S–2424S. 2003.PubMed/NCBI
|
|
4
|
Ogawa K, Hara T, Shimizu M, Nagano J, Ohno
T, Hoshi M, Ito H, Tsurumi H, Saito K, Seishima M, et al:
(−)-Epigallocatechin gallate inhibits the expression of indoleamine
2,3-dioxygenase in human colorectal cancer cells. Oncol Lett.
4:546–550. 2012.
|
|
5
|
Kim JW, Amin AR and Shin DM:
Chemoprevention of head and neck cancer with green tea polyphenols.
Cancer Prev Res (Phila). 3:900–909. 2010. View Article : Google Scholar
|
|
6
|
Oh TY, Lee JS, Ahn BO, Cho H, Kim WB, Kim
YB, Surh YJ, Cho SW, Lee KM and Hahm KB: Oxidative stress is more
important than acid in the pathogenesis of reflux oesophagitis in
rats. Gut. 49:364–371. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cheong JH, Hong SY, Zheng Y and Noh SH:
Eupatilin inhibits gastric cancer cell growth by blocking
STAT3-mediated VEGF expression. J Gastric Cancer. 11:16–22. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cho JH, Lee JG, Yang YI, Kim JH, Ahn JH,
Baek NI, Lee KT and Choi JH: Eupatilin, a dietary flavonoid,
induces G2/M cell cycle arrest in human endometrial cancer cells.
Food Chem Toxicol. 49:1737–1744. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim MJ, Kim DH, Na HK, Oh TY, Shin CY and
Surh YJ: Eupatilin, a pharmacologically active flavone derived from
Artemisia plants, induces apoptosis in human gastric cancer (AGS)
cells. J Environ Pathol Toxicol Oncol. 24:261–269. 2005. View Article : Google Scholar
|
|
10
|
Park BB, Yoon J, Kim E, Choi J, Won Y,
Choi J and Lee YY: Inhibitory effects of eupatilin on tumor
invasion of human gastric cancer MKN-1 cells. Tumour Biol.
34:875–885. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vanhaesebroeck B, Guillermet-Guibert J,
Graupera M and Bilanges B: The emerging mechanisms of
isoform-specific PI3K signalling. Nat Rev Mol Cell Biol.
11:329–341. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thorpe LM, Yuzugullu H and Zhao JJ: PI3K
in cancer: Divergent roles of isoforms, modes of activation and
therapeutic targeting. Nat Rev Cancer. 15:7–24. 2015. View Article : Google Scholar :
|
|
15
|
Shukla S and Gupta S: Apigenin-induced
cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and
loss of cyclin D1 associated retinoblastoma dephosphorylation in
human prostate cancer cells. Cell Cycle. 6:1102–1114. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gershtein ES, Scherbakov AM, Shatskaya VA,
Kushlinsky NE and Krasil’nikov MA: Phosphatidylinositol
3-kinase/AKT signalling pathway components in human breast cancer:
Clinicopathological correlations. Anticancer Res. 27:1777–1782.
2007.PubMed/NCBI
|
|
17
|
Altomare DA and Testa JR: Perturbations of
the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Leis H, Segrelles C, Ruiz S, Santos M and
Paramio JM: Expression, localization, and activity of glycogen
synthase kinase 3beta during mouse skin tumorigenesis. Mol
Carcinog. 35:180–185. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Diehl JA, Cheng M, Roussel MF and Sherr
CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis
and subcellular localization. Genes Dev. 12:3499–3511. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ahmad N, Feyes DK, Nieminen AL, Agarwal R
and Mukhtar H: Green tea constituent epigallocatechin-3-gallate and
induction of apoptosis and cell cycle arrest in human carcinoma
cells. J Natl Cancer Inst. 89:1881–1886. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen P, Deng YL, Bergqvist S, Falk MD, Liu
W, Timofeevski S and Brooun A: Engineering of an isolated p110α
subunit of PI3Kα permits crystallization and provides a platform
for structure-based drug design. Protein Sci. 23:1332–1340. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Frisch MJ, Trucks MJ, Schlegel HB,
Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Mennucci
B and Petersson GA: Gaussian 09, Revision A. 02. Gaussian. Inc.;
Wallingford, CT: 2009
|
|
24
|
Bayly C, Cieplak P, Cornell WD and Kollman
PA: A well-behaved electrostatic potential based method using
charge restraints for deriving atomic charges: the RESP model. J
Phys Chem. 97:10269–10280. 1993. View Article : Google Scholar
|
|
25
|
Morris GM, Goodsell DS, Halliday RS, Huey
R, Hart WE, Belew RK and Olson AJ: Automated docking using a
Lamarckian Genetic Algorithm and empirical binding free energy
function. J Comput Chem. 19:1639–1662. 1998. View Article : Google Scholar
|
|
26
|
Solis FJ and Wets R: Minimization by
random search techniques. Math Oper Res. 6:19–30. 1981. View Article : Google Scholar
|
|
27
|
Demidenko ZN and Blagosklonny MV: Growth
stimulation leads to cellular senescence when the cell cycle is
blocked. Cell Cycle. 7:3355–3361. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gong C, Liao H, Wang J, Lin Y, Qi J, Qin
L, Tian LQ and Guo FJ: LY294002 induces G0/G1 cell cycle arrest and
apoptosis of cancer stem-like cells from human osteosarcoma via
down-regulation of PI3K activity. Asian Pac J Cancer Prev.
13:3103–3107. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bode AM and Dong Z: Molecular and cellular
targets. Mol Carcinog. 45:422–430. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dong Z, Crawford HC, Lavrovsky V, Taub D,
Watts R, Matrisian LM and Colburn NH: A dominant negative mutant of
jun blocking 12-O-tetradecanoylphorbol-13-acetate-induced invasion
in mouse keratinocytes. Mol Carcinog. 19:204–212. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang C, Ma WY, Young MR, Colburn N and
Dong Z: Shortage of mitogen-activated protein kinase is responsible
for resistance to AP-1 transactivation and transformation in mouse
JB6 cells. Proc Natl Acad Sci USA. 95:156–161. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nomura M, Ichimatsu D, Moritani S, Koyama
I, Dong Z, Yokogawa K and Miyamoto K: Inhibition of epidermal
growth factor-induced cell transformation and Akt activation by
caffeine. Mol Carcinog. 44:67–76. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lu Z, Ghosh S, Wang Z and Hunter T:
Downregulation of caveolin-1 function by EGF leads to the loss of
E-cadherin, increased transcriptional activity of beta-catenin, and
enhanced tumor cell invasion. Cancer Cell. 4:499–515. 2003.
View Article : Google Scholar
|
|
34
|
Mooradian DL and Diglio CA: Effects of
epidermal growth factor and transforming growth factor-beta 1 on
rat heart endothelial cell anchorage-dependent and -independent
growth. Exp Cell Res. 186:122–129. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee CJ, Jang JH, Lee JY, Lee MH, Li Y, Ryu
HW, Choi KI, Dong Z, Lee HS, Oh SR, et al: Aschantin targeting on
the kinase domain of mammalian target of rapamycin suppresses
epidermal growth factor-induced neoplastic cell transformation.
Carcinogenesis. 36:1223–1234. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lim JC, Park SY, Nam Y, Nguyen TT and Sohn
UD: The protective effect of eupatilin against hydrogen
peroxide-induced injury involving 5-lipoxygenase in feline
esophageal epithelial cells. Korean J Physiol Pharmacol.
16:313–320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu K, Park C, Li S, Lee KW, Liu H, He L,
Soung NK, Ahn JS, Bode AM, Dong Z, et al: Aloe-emodin suppresses
prostate cancer by targeting the mTOR complex 2. Carcinogenesis.
33:1406–1411. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gao N, Zhang Z, Jiang BH and Shi X: Role
of PI3K/AKT/mTOR signaling in the cell cycle progression of human
prostate cancer. Biochem Biophys Res Commun. 310:1124–1132. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yap TA, Garrett MD, Walton MI, Raynaud F,
de Bono JS and Workman P: Targeting the PI3K-AKT-mTOR pathway:
Progress, pitfalls, and promises. Curr Opin Pharmacol. 8:393–412.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bachman KE, Argani P, Samuels Y, Silliman
N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, et al:
The PIK3CA gene is mutated with high frequency in human breast
cancers. Cancer Biol Ther. 3:772–775. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Broderick DK, Di C, Parrett TJ, Samuels
YR, Cummins JM, McLendon RE, Fults DW, Velculescu VE, Bigner DD and
Yan H: Mutations of PIK3CA in anaplastic oligodendrogliomas,
high-grade astrocytomas, and medulloblastomas. Cancer Res.
64:5048–5050. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Samuels Y, Wang Z, Bardelli A, Silliman N,
Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al:
High frequency of mutations of the PIK3CA gene in human cancers.
Science. 304:5542004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jin YJ, Lee JH, Kim YM, Oh GT and Lee H:
Macrophage inhibitory cytokine-1 stimulates proliferation of human
umbilical vein endothelial cells by up-regulating cyclins D1 and E
through the PI3K/Akt-, ERK-, and JNK-dependent AP-1 and E2F
activation signaling pathways. Cell Signal. 24:1485–1495. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sarker D and Workman P: Pharmacodynamic
biomarkers for molecular cancer therapeutics. Adv Cancer Res.
96:213–268. 2007. View Article : Google Scholar
|
|
45
|
Osaki M, Oshimura M and Ito H: PI3K-Akt
pathway: Its functions and alterations in human cancer. Apoptosis.
9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Patel S: Exploring novel therapeutic
targets in GIST: Focus on the PI3K/Akt/mTOR pathway. Curr Oncol
Rep. 15:386–395. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Slomovitz BM and Coleman RL: The
PI3K/AKT/mTOR pathway as a therapeutic target in endometrial
cancer. Clin Cancer Res. 18:5856–5864. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mishra R: Glycogen synthase kinase 3 beta:
Can it be a target for oral cancer. Mol Cancer. 9:1442010.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ma C, Wang J, Gao Y, Gao TW, Chen G, Bower
KA, Odetallah M, Ding M, Ke Z and Luo J: The role of glycogen
synthase kinase 3beta in the transformation of epidermal cells.
Cancer Res. 67:7756–7764. 2007. View Article : Google Scholar : PubMed/NCBI
|
